{"id":390774,"date":"2017-12-19T00:00:00","date_gmt":"2017-12-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0005-2017-biopharma-non-small-cell-lung-cancer-current-treatment-us-2017\/"},"modified":"2026-03-31T10:49:07","modified_gmt":"2026-03-31T10:49:07","slug":"cutron0005-2017-biopharma-non-small-cell-lung-cancer-current-treatment-us-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0005-2017-biopharma-non-small-cell-lung-cancer-current-treatment-us-2017\/","title":{"rendered":"Non-Small-Cell Lung Cancer | Current Treatment | US | 2017"},"content":{"rendered":"<p>NSCLC\u00a0is one of the most dynamic indications in oncology. In the United States, the\u00a0FDAapproved six new therapies for\u00a0NSCLC\u00a0in 2015 and, in 2016, granted approval to Tecentriq (Roche\/Genentech), the third immune checkpoint inhibitor to launch for this indication. In addition, Keytruda (Merck &#038; Co.) is the first\u00a0PD-1\u00a0inhibitor to enter the commercially lucrative first-line metastatic\u00a0NSCLC\u00a0setting, with an\u00a0FDA\u00a0label expansion awarded for\u00a0PD-L1-positive patients in 2016. As a result, the current treatment algorithm for metastatic\u00a0NSCLC\u00a0is continuously evolving, including in biomarker-driven populations such as\u00a0<em>EGFR<\/em>-mutation-positive and\u00a0<em>ALK<\/em>-translocation-negative patients.<\/p>\n<p><strong>Questions\u00a0Answered:<\/strong><\/p>\n<ul>\n<li>What is the uptake of Keytruda in the first-line metastatic\u00a0NSCLC\u00a0setting, according to surveyed\u00a0U.S.\u00a0medical oncologists?<\/li>\n<li>What percentage of second-line metastatic patients receive the recently approved agent Tecentriq, and which factors drive prescribing?<\/li>\n<li>What is the most preferred sequence of treatment in select biomarker-defined metastatic\u00a0NSCLC\u00a0populations?<\/li>\n<li>How do drug-treatment rates vary between key metastatic\u00a0NSCLC\u00a0patient segments, according to biomarker status and line of therapy?<\/li>\n<\/ul>\n<p><strong>Product\u00a0Description:<\/strong><\/p>\n<p>Current Treatment: Provides physician insights on prescribing behavior, treatment paths, and the factors and perceptions driving brand usage so you can understand each brand\u2019s performance and improve or defend your competitive position.<\/p>\n","protected":false},"template":"","class_list":["post-390774","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-non-small-cell-lung-cancer","biopharma-therapy-areas-small-cell-lung-cancer","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390774","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390774\/revisions"}],"predecessor-version":[{"id":576765,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390774\/revisions\/576765"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}